% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Galldiks:1024009,
author = {Galldiks, Norbert and Kaufmann, Timothy J and Vollmuth,
Philipp and Lohmann, Philipp and Smits, Marion and Veronesi,
Michael C and Langen, Karl-Josef and Rudá, Roberta and
Albert, Nathalie L and Hattingen, Elke and Law, Ian and
Hutterer, Markus and Soffietti, Riccardo and Vogelbaum,
Michael A and Wen, Patrick Y and Weller, Michael and Tonn,
Joerg-Christian},
title = {{C}hallenges, {L}imitations and {P}itfalls of {PET} and
{A}dvanced {MRI} in {P}atients with {B}rain {T}umors - {A}
{R}eport of the {PET}/{RANO} {G}roup},
journal = {Neuro-Oncology},
volume = {26},
number = {7},
issn = {1522-8517},
address = {Oxford},
publisher = {Oxford Univ. Press},
reportid = {FZJ-2024-01908},
pages = {1181-1194},
year = {2024},
abstract = {Brain tumor diagnostics have significantly evolved with the
use of positron emission tomography (PET) and advanced
magnetic resonance imaging (MRI) techniques. In addition to
anatomical MRI, these modalities may provide valuable
information for several clinical applications such as
differential diagnosis, delineation of tumor extent,
prognostication, differentiation between tumor relapse and
treatment-related changes, and the evaluation of response to
anticancer therapy. In particular, joint recommendations of
the Response Assessment in Neuro-Oncology (RANO) Group, the
European Association of Neuro-oncology, and major European
and American Nuclear Medicine societies highlighted that the
additional clinical value of radiolabeled amino acids
compared to anatomical MRI alone is outstanding and that its
widespread clinical use should be supported. For advanced
MRI and its steadily increasing use in clinical practice,
the Standardization Subcommittee of the Jumpstarting Brain
Tumor Drug Development Coalition provided more recently an
updated acquisition protocol for the widely used dynamic
susceptibility contrast perfusion MRI. Besides amino acid
PET and perfusion MRI, other PET tracers and advanced MRI
techniques (e.g. MR spectroscopy) are of considerable
clinical interest and are increasingly integrated into
everyday clinical practice. Nevertheless, these modalities
have shortcomings which should be considered in clinical
routine. This comprehensive review provides an overview of
potential challenges, limitations, and pitfalls associated
with PET imaging and advanced MRI techniques in patients
with gliomas or brain metastases. Despite these issues, PET
imaging and advanced MRI techniques continue to play an
indispensable role in brain tumor management. Acknowledging
and mitigating these challenges through interdisciplinary
collaboration, standardized protocols, and continuous
innovation will further enhance the utility of these
modalities in guiding optimal patient care.},
cin = {INM-3},
ddc = {610},
cid = {I:(DE-Juel1)INM-3-20090406},
pnm = {5252 - Brain Dysfunction and Plasticity (POF4-525)},
pid = {G:(DE-HGF)POF4-5252},
typ = {PUB:(DE-HGF)16},
pubmed = {38466087},
UT = {WOS:001196533900001},
doi = {10.1093/neuonc/noae049},
url = {https://juser.fz-juelich.de/record/1024009},
}